101 related articles for article (PubMed ID: 15824741)
21. Alternative splicing regulation at tandem 3' splice sites.
Akerman M; Mandel-Gutfreund Y
Nucleic Acids Res; 2006; 34(1):23-31. PubMed ID: 16394021
[TBL] [Abstract][Full Text] [Related]
22. The effect of disease-associated HRPT2 mutations on splicing.
Hahn MA; McDonnell J; Marsh DJ
J Endocrinol; 2009 Jun; 201(3):387-96. PubMed ID: 19332451
[TBL] [Abstract][Full Text] [Related]
23. The cytochrome P450 aromatase lacking exon 5 is associated with a phenotype of nonclassic aromatase deficiency and is also present in normal human steroidogenic tissues.
Pepe CM; Saraco NI; Baquedano MS; Guercio G; Vaiani E; Marino R; Pandey AV; Flück CE; Rivarola MA; Belgorosky A
Clin Endocrinol (Oxf); 2007 Nov; 67(5):698-705. PubMed ID: 17608756
[TBL] [Abstract][Full Text] [Related]
24. Mid-frequency DFNA8/12 hearing loss caused by a synonymous TECTA mutation that affects an exonic splice enhancer.
Collin RW; de Heer AM; Oostrik J; Pauw RJ; Plantinga RF; Huygen PL; Admiraal R; de Brouwer AP; Strom TM; Cremers CW; Kremer H
Eur J Hum Genet; 2008 Dec; 16(12):1430-6. PubMed ID: 18575463
[TBL] [Abstract][Full Text] [Related]
25. KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized?
Fletcher JA; Fletcher CD; Rubin BP; Ashman LK; Corless CL; Heinrich MC
Am J Pathol; 2002 Aug; 161(2):737-8; author reply 738-9. PubMed ID: 12163398
[No Abstract] [Full Text] [Related]
26. A strong exonic splicing enhancer in dystrophin exon 19 achieve proper splicing without an upstream polypyrimidine tract.
Habara Y; Doshita M; Hirozawa S; Yokono Y; Yagi M; Takeshima Y; Matsuo M
J Biochem; 2008 Mar; 143(3):303-10. PubMed ID: 18039686
[TBL] [Abstract][Full Text] [Related]
27. Distribution of exonic splicing enhancer elements in human genes.
Wu Y; Zhang Y; Zhang J
Genomics; 2005 Sep; 86(3):329-36. PubMed ID: 16005179
[TBL] [Abstract][Full Text] [Related]
28. In vitro splicing analysis showed that availability of a cryptic splice site is not a determinant for alternative splicing patterns caused by +1G-->A mutations in introns of the dystrophin gene.
Habara Y; Takeshima Y; Awano H; Okizuka Y; Zhang Z; Saiki K; Yagi M; Matsuo M
J Med Genet; 2009 Aug; 46(8):542-7. PubMed ID: 19001018
[TBL] [Abstract][Full Text] [Related]
29. A deep intronic mutation in FGB creates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment.
Davis RL; Homer VM; George PM; Brennan SO
Hum Mutat; 2009 Feb; 30(2):221-7. PubMed ID: 18853456
[TBL] [Abstract][Full Text] [Related]
30. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
[TBL] [Abstract][Full Text] [Related]
31. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
Bertucci F; Goncalves A; Monges G; Madroszyk A; Guiramand J; Moutardier V; Noguchi T; Dubreuil P; Sobol H
Oncol Rep; 2006 Jul; 16(1):97-101. PubMed ID: 16786129
[TBL] [Abstract][Full Text] [Related]
32. A novel SLC12A3 splicing mutation skipping of two exons and preliminary screening for alternative splice variants in human kidney.
Shao L; Liu L; Miao Z; Ren H; Wang W; Lang Y; Yue S; Chen N
Am J Nephrol; 2008; 28(6):900-7. PubMed ID: 18580052
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical and mutational analysis of c-kit in gastrointestinal neuroendocrine cell carcinoma.
Ishikubo T; Akagi K; Kurosumi M; Yamaguchi K; Fujimoto T; Sakamoto H; Tanaka Y; Ochiai A
Jpn J Clin Oncol; 2006 Aug; 36(8):494-8. PubMed ID: 16844734
[TBL] [Abstract][Full Text] [Related]
34. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
35. Distribution of SR protein exonic splicing enhancer motifs in human protein-coding genes.
Wang J; Smith PJ; Krainer AR; Zhang MQ
Nucleic Acids Res; 2005; 33(16):5053-62. PubMed ID: 16147989
[TBL] [Abstract][Full Text] [Related]
36. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
[TBL] [Abstract][Full Text] [Related]
37. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
38. A G-to-A transition at the fifth position of intron-32 of the dystrophin gene inactivates a splice-donor site both in vivo and in vitro.
Thi Tran HT; Takeshima Y; Surono A; Yagi M; Wada H; Matsuo M
Mol Genet Metab; 2005 Jul; 85(3):213-9. PubMed ID: 15979033
[TBL] [Abstract][Full Text] [Related]
39. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).
Ali S; Ali S
Gene; 2007 Oct; 401(1-2):38-45. PubMed ID: 17659849
[TBL] [Abstract][Full Text] [Related]
40. Frequent c-Kit gene mutations not only in gastrointestinal stromal tumors but also in interstitial cells of Cajal in surrounding normal mucosa.
Ogasawara N; Tsukamoto T; Inada K; Mizoshita T; Ban N; Yamao K; Joh T; Itoh M; Tatematsu M
Cancer Lett; 2005 Dec; 230(2):199-210. PubMed ID: 16297706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
